[go: up one dir, main page]

AR102048A1 - Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina - Google Patents

Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina

Info

Publication number
AR102048A1
AR102048A1 ARP150102587A ARP150102587A AR102048A1 AR 102048 A1 AR102048 A1 AR 102048A1 AR P150102587 A ARP150102587 A AR P150102587A AR P150102587 A ARP150102587 A AR P150102587A AR 102048 A1 AR102048 A1 AR 102048A1
Authority
AR
Argentina
Prior art keywords
factor
furina
secretion
expression system
functional
Prior art date
Application number
ARP150102587A
Other languages
English (en)
Inventor
Dockal Michael
Koehn Jadranka
Horling Franziska
Bhm Ernst
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of AR102048A1 publication Critical patent/AR102048A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se revelan métodos para la producción del Factor X maduro completamente procesado en un sistema de expresión que produce una cantidad controlada de furina entre 50 U/mL y 300 U/mL del sobrenadante de cultivo. También se revelan. células transformadas, sistemas de expresión y vectores de expresión para la expresión de furina y el Factor X.
ARP150102587A 2014-08-12 2015-08-11 Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina AR102048A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462036438P 2014-08-12 2014-08-12

Publications (1)

Publication Number Publication Date
AR102048A1 true AR102048A1 (es) 2017-02-01

Family

ID=54035298

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102587A AR102048A1 (es) 2014-08-12 2015-08-11 Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina

Country Status (14)

Country Link
US (1) US9873892B2 (es)
EP (1) EP3180427B1 (es)
JP (1) JP6793114B2 (es)
CN (1) CN107002041B (es)
AR (1) AR102048A1 (es)
AU (1) AU2015301726B2 (es)
CA (1) CA2958056C (es)
EA (1) EA035444B1 (es)
ES (1) ES2742724T3 (es)
IL (1) IL250530B (es)
MX (1) MX377236B (es)
NZ (1) NZ729729A (es)
TW (1) TWI666319B (es)
WO (1) WO2016025615A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies
WO2020257942A1 (en) * 2019-06-28 2020-12-30 Peel Sean A F A method for increasing yields and the specific activity of certain recombinant proteins in mammalian cells by co-expressing full-length furin
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
WO2023141754A1 (zh) * 2022-01-25 2023-08-03 青岛万明赛伯药业有限公司 proNGF突变体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0574402T3 (da) * 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
WO2004101598A2 (en) * 2003-05-09 2004-11-25 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
PT1969127E (pt) * 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
AU2008254522B2 (en) * 2007-05-18 2012-07-12 Takeda Pharmaceutical Company Limited Method for producing mature VWF from VWF pro-peptide
WO2009088713A1 (en) * 2007-12-31 2009-07-16 Baxter International Inc. Substantially animal protein-free recombinant furin and methods for producing same
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
SG195261A1 (en) * 2011-06-02 2013-12-30 Baxter Int Formulations of recombinant furin

Also Published As

Publication number Publication date
TWI666319B (zh) 2019-07-21
IL250530B (en) 2020-03-31
EP3180427B1 (en) 2019-05-22
EP3180427A1 (en) 2017-06-21
JP6793114B2 (ja) 2020-12-09
CA2958056C (en) 2023-07-04
WO2016025615A1 (en) 2016-02-18
AU2015301726B2 (en) 2021-10-21
CN107002041A (zh) 2017-08-01
IL250530A0 (en) 2017-03-30
TW201625791A (zh) 2016-07-16
MX377236B (es) 2025-03-07
EA035444B1 (ru) 2020-06-17
CN107002041B (zh) 2021-06-29
MX2017001931A (es) 2017-06-30
US9873892B2 (en) 2018-01-23
ES2742724T3 (es) 2020-02-17
US20160046957A1 (en) 2016-02-18
EA201790360A1 (ru) 2017-06-30
AU2015301726A1 (en) 2017-03-16
NZ729729A (en) 2023-07-28
CA2958056A1 (en) 2016-02-18
JP2017524366A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2021004479A (es) Agentes biologicos y su uso en plantas.
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
MX2019003489A (es) Moleculas del receptor de envolvimiento quimerico.
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
MX2016014235A (es) Biosintesis microbiana de ergotioneina.
CL2017001227A1 (es) Ganado lechero híbrido y sistemas para maximizar la ventaja híbrida.
MX363690B (es) Expansión de celulas madre adultas in vitro.
AR090319A1 (es) Biorrefineria integrada
MX2016013950A (es) Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica.
FI20140266A7 (fi) Menetelmä ja laite nanopartikkeleiden valmistamiseksi
MY193650A (en) Extracellular matrix compositions
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
AR102048A1 (es) Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina
SG11201806642QA (en) Heat storage particles, method for producing same, and heat storage material
MX2023014907A (es) Forma solida de (-)-ambrox formada por una biconversion de homofarnesol en presencia de un biocatalizador.
RU2013125729A (ru) Способ повышения продуктивности крупного рогатого скота
MX2022000516A (es) Metodos relacionados con celulas pluripotentes.
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
AR099810A1 (es) Microorganismos que producen aminoácidos l y proceso para producir aminoácidos l utilizándolos
WO2015101243A8 (zh) 雌性不育系的繁殖及杂交制种技术
EP3194573A4 (en) Mammalian pluripotent stem cells, methods for their production, and uses thereof
MX2017010670A (es) Alimento en forma de gel para lechoncillos, metodo para manufacturar el mismo y uso.
BR112017009450A2 (pt) ?produção de células bacterianas tindalizadas, intactas e imunologicamente ativas de lactobacillus rhamnosus gg (atcc 53103) e método para a determinação qualitativa e quantitativa das mesmas?